East Windsor, NJ—Sabinsa’s Founder, Chairman, and Managing Director Dr. Muhammed Majeed announced the publication of a new book, titled Reductive Metabolites of Curcuminoids in a press release.
Authored by Dr. Majeed and N. Kalyanam, Ph.D., President of R&D at Sabinsa, as well as other members of the Sami-Sabinsa Group’s technical staff, the book walks through the transformation of curcumin into its metabolites inside the body, and discusses the significance of major metabolites. The book also reviews the scientific evidence on the effects of microbiota on what has been called “poor bioavailability,” and discusses the unmistakable role of microbiota in transforming curcumin into its major pharmacologically potent reductive metabolite, tetrahydrocurcumin.
Related: Company Profile: Sabinsa
Sabinsa’s C3 Reduct Self-Affirmed GRAS
Study: Curcumin, BioPerine Potentially Beneficial for Mesothelioma Patients
Dr. Majeed said in the release: “The central theme of the book is to emphasize that the effects of curcumin observed in animal models and in human trials are the aggregate benefits of curcumin and the reductive metabolites of curcuminoids.”
The Sabinsa staff will have copies of the book at booth #4131 at SupplySide West in Las Vegas, NV, October 17-18.